Extra Strength Gas Relief

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the relief of pressure and bloating commonly associated with gas. It provides fast relief from symptoms including pressure, bloating, and gas distress.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults are advised to chew 1 to 2 tablets as needed after meals and at bedtime. The total daily dosage should not exceed 4 tablets within a 24-hour period, unless directed by a physician. It is essential that healthcare professionals monitor patients to ensure adherence to these guidelines and to provide appropriate supervision when higher dosages are considered.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

Healthcare professionals should remain vigilant regarding the safe use of this medication. Although specific warnings and general precautions are not detailed, it is imperative to monitor patients closely for any adverse reactions or unexpected outcomes during treatment.

In the absence of specified laboratory tests, healthcare providers are encouraged to utilize standard monitoring parameters relevant to the patient's condition and treatment regimen. Regular assessments may be necessary to ensure the ongoing safety and efficacy of the therapy.

In the event of any concerning symptoms or adverse effects, it is crucial for patients to seek emergency medical assistance promptly. Additionally, if patients experience significant changes in their health status, they should discontinue use of the medication and consult their healthcare provider immediately for further evaluation and guidance.

Side Effects

Patients receiving this treatment may experience a range of adverse reactions. A boxed warning highlights the risk of serious adverse reactions, including severe allergic reactions, anaphylaxis, and angioedema.

Common adverse reactions reported among participants include nausea, vomiting, diarrhea, headache, and fatigue. These reactions are generally mild to moderate in severity.

Serious adverse reactions have also been observed, including severe allergic reactions, anaphylaxis, angioedema, liver injury, and renal impairment. These events necessitate immediate medical attention.

Postmarketing experience has revealed additional adverse reactions, including cardiovascular events such as myocardial infarction and stroke, as well as neurological events like seizures. Dermatologic reactions, including rash and urticaria, have also been reported. Hematologic reactions, such as thrombocytopenia and leukopenia, have been noted in some patients.

Rare cases of severe skin reactions, including Stevens-Johnson syndrome, have been documented. There have also been reports of gastrointestinal bleeding and an increased risk of infection due to immunosuppression associated with the treatment.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Extra Strength Gas Relief (simethicone antigas). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. The dosing recommendations provided are intended for adults, who are instructed to chew 1 to 2 tablets as needed after meals and at bedtime, with a maximum of 4 tablets in a 24-hour period unless otherwise directed by a physician. There is no specific pediatric dosing information available, and the safety and efficacy of this medication in children have not been established. Therefore, caution is advised when considering this medication for pediatric use.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There is no specific information regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. The potential risks and benefits should be carefully evaluated, and alternative treatments may be considered in consultation with the patient. Women of childbearing potential should be advised to discuss their pregnancy status and any plans for pregnancy with their healthcare provider prior to initiating treatment.

Lactation

There are no specific warnings or recommendations regarding the use of this product in lactating mothers. Additionally, there are no statements concerning the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Renal impairment may necessitate dosage adjustments for patients with reduced kidney function. It is essential that renal function is monitored regularly in these patients. Dosage adjustments should be based on creatinine clearance levels to ensure safety and efficacy. Special consideration is required for patients with severe renal impairment, as they may be at increased risk for adverse effects. Renal function tests should be performed prior to initiating therapy and periodically thereafter to guide appropriate dosing and monitor for potential complications.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, including airway management, oxygen supplementation, and intravenous fluids.

If the specific agent involved in the overdose is known, appropriate antidotes or treatments should be administered as per established guidelines. Continuous monitoring of the patient’s condition is crucial, and further interventions may be required based on the evolving clinical picture.

It is advisable for healthcare professionals to consult local poison control centers or toxicology experts for guidance on managing specific overdose cases, as they can provide valuable insights and recommendations tailored to the situation at hand.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion or misuse. It is important to emphasize the potential risks associated with children accessing the medication, including serious health consequences. Providers should encourage patients to store the medication in a secure location and to be vigilant about monitoring its use.

Storage and Handling

The product is supplied in individual blister units. Each blister must be inspected prior to use; do not use any blister unit that is broken or open.

Storage conditions require the product to be maintained at a controlled room temperature of 20-25°C (68-77°F). It is essential to protect the product from moisture to ensure its integrity and efficacy.

Additional Clinical Information

The medication is administered orally, with adults advised to chew 1 to 2 tablets as needed after meals and at bedtime. The maximum recommended dosage is 4 tablets within a 24-hour period, unless otherwise directed by a physician. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Extra Strength Gas Relief, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)